CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 58 enrolled
Drug / intervention
Mifepristone +1 moredrug
Likely dose
Mifepristone 600mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01134198
NCT01134198Phase 3Completed
CompareCT.gov

Investigation of the Effects of Mifepristone (RU486) on Stress Sensitivity and Relapse Prevention in Cocaine Dependent Patients

New York State Psychiatric Institute·interventional·Posted May 31, 2010·Updated Dec 20, 2018

In Brief

A Phase 3 clinical trial evaluating Mifepristone and placebo for Cocaine Dependence. Completed, enrolled 58 participants across 1 site.

Detailed Summary

This research will evaluate the impact of blocking central and peripheral glucocorticoid receptors on stress sensitivity and the risk of relapse to cocaine use in treatment-seeking cocaine-dependent individuals. Mifepristone (RU-486) will be the glucocorticoid antagonist used.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCocaine Dependence
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 31, 2010
Enrollment StartMay 1, 2010
Primary CompletionSep 1, 2016
Study CompletionFeb 14, 2018
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 16.1 years ago

Interventions

Mifepristonedrug

Mifepristone 600mg, 3x/wk for 4 weeks

placebodrug

placebo